Prognostic value of different biomarkers in bladder cancer: protocol for an umbrella review of systematic reviews and meta-analyses.
Summary
This article outlines the protocol for an umbrella review aiming to synthesize evidence on prognostic biomarkers in bladder cancer. The objective is to compare all identified prognostic biomarkers in the literature to assess their clinical value. The authors plan to search systematic reviews and meta-analyses across multiple databases, extract relevant data, and assess the risk of bias. Statistical analysis will include pooled HR estimation, evaluation of heterogeneity and small-study effects, and an assessment of evidence credibility.
Analysis
This umbrella review protocol addresses a critical clinical need to clarify the prognostic value of biomarkers in bladder cancer, a field where no biomarker has yet been implemented in clinical practice. By synthesizing evidence from multiple systematic reviews, it aims to identify the most promising biomarkers and provide a robust foundation for future clinical validation studies. The findings could justify phase III clinical trials for the most robust biomarkers, potentially leading to changes in bladder cancer patient management guidelines within a 3-5 year timeframe, by improving risk stratification and treatment personalization.